EP4090686A4 - Pro-antikörper, der die off-target-toxizität reduziert - Google Patents

Pro-antikörper, der die off-target-toxizität reduziert Download PDF

Info

Publication number
EP4090686A4
EP4090686A4 EP21741991.0A EP21741991A EP4090686A4 EP 4090686 A4 EP4090686 A4 EP 4090686A4 EP 21741991 A EP21741991 A EP 21741991A EP 4090686 A4 EP4090686 A4 EP 4090686A4
Authority
EP
European Patent Office
Prior art keywords
pro
antibody
reduces
target toxicity
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741991.0A
Other languages
English (en)
French (fr)
Other versions
EP4090686A2 (de
Inventor
Kuo-Fu TSENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Targeting Inc
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority claimed from PCT/US2021/013688 external-priority patent/WO2021146590A2/en
Publication of EP4090686A2 publication Critical patent/EP4090686A2/de
Publication of EP4090686A4 publication Critical patent/EP4090686A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21741991.0A 2020-01-17 2021-01-15 Pro-antikörper, der die off-target-toxizität reduziert Pending EP4090686A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062962555P 2020-01-17 2020-01-17
PCT/US2021/013688 WO2021146590A2 (en) 2020-01-17 2021-01-15 Pro-antibody that reduces off-target toxicity

Publications (2)

Publication Number Publication Date
EP4090686A2 EP4090686A2 (de) 2022-11-23
EP4090686A4 true EP4090686A4 (de) 2024-03-27

Family

ID=82906067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741991.0A Pending EP4090686A4 (de) 2020-01-17 2021-01-15 Pro-antikörper, der die off-target-toxizität reduziert

Country Status (2)

Country Link
EP (1) EP4090686A4 (de)
CN (1) CN114945597A (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. BOND PROTEINS WITH RESTRICTED CONDITIONAL ACTIVATION

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
ES2721882T3 (es) * 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
IN2014MN02164A (de) * 2012-04-27 2015-08-28 Cytomx Therapeutics Inc
EP3049111A2 (de) * 2013-09-25 2016-08-03 Cytomx Therapeutics Inc. Matrix-metalloproteinasesubstrate und andere spaltbare elemente sowie verfahren zur verwendung davon
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
CN107709363A (zh) * 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3313874B1 (de) * 2015-06-26 2021-03-10 University of Southern California Maskierung von chimären antigenrezeptor-t-zellen zur tumorspezifischen aktivierung
US11466093B2 (en) * 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
WO2017205741A1 (en) * 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN110662766A (zh) * 2017-03-09 2020-01-07 赛托姆克斯治疗学股份有限公司 Cd147抗体、可激活cd147抗体及其制备和使用方法
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2020246563A1 (ja) * 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
EP4126955A1 (de) * 2020-03-26 2023-02-08 Aetio Biotherapy, Inc. Bispezifische fusionsproteine zur abreicherung regulatorischer t-zellen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. BOND PROTEINS WITH RESTRICTED CONDITIONAL ACTIVATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANG SHANSHAN ET AL: "LegoBody: facile generation of bispecific and multi-specific antibodies", BIORXIV, 27 December 2019 (2019-12-27), XP093129094, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2019.12.25.888586v1.full.pdf> [retrieved on 20240208], DOI: 10.1101/2019.12.25.888586 *

Also Published As

Publication number Publication date
CN114945597A (zh) 2022-08-26
EP4090686A2 (de) 2022-11-23

Similar Documents

Publication Publication Date Title
EP4090686A4 (de) Pro-antikörper, der die off-target-toxizität reduziert
AU2021901309A0 (en) Tr3k board
AU2021901191A0 (en) Tre3k board
AU2022213445A9 (en) E-cut sealer-divider
AU2021904022A0 (en) ColourMakesItClear
AU2021903826A0 (en) Iceglass
AU2021903650A0 (en) agtech
AU2021903423A0 (en) Easy-Grab
AU2021903322A0 (en) Eycsar
AU2021902982A0 (en) P1565au03
AU2021902800A0 (en) Enviro-lid-catch
AU2021902772A0 (en) MyHerculead
AU2021902428A0 (en) Antenna2
AU2021902077A0 (en) Si-211
AU2021901795A0 (en) Build-A-bouquet
AU2021901682A0 (en) PoPLeveLPoP
AU2021900733A0 (en) Mudgutz
AU2021900525A0 (en) BubbleSplint
AU2021900524A0 (en) Gyroball
AU2021900362A0 (en) Tab-Sleeve
AU2021900327A0 (en) Ridball
AU2021900190A0 (en) Stumpmate
AU2021900191A0 (en) Omni-wheel
AU2021900077A0 (en) CareSide
AU2020904618A0 (en) SafeForce

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNE TARGETING INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20240227

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20240221BHEP

Ipc: A61P 37/02 20060101ALI20240221BHEP

Ipc: A61P 17/06 20060101ALI20240221BHEP

Ipc: A61P 35/00 20060101ALI20240221BHEP

Ipc: C07K 16/30 20060101AFI20240221BHEP